EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Engineered Mesenchymal Stem Cell–Derived Extracellular Vesicles Reverse Endothelial–Mesenchymal Transition in Atherosclerosis

Zhuo Chen, Kai Chang, Sha Yang, Ruijia Deng, Yuan He, Ligai Zhang, Ming Chen iD, Dingqun Bai, Yan Pi iD

Journal of Extracellular Vesicles · 2025-06 · 14 (6)

DOI: 10.1002/jev2.70099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 23.06.2025. Verfasst von Zhuo Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Medicine, Key Laboratory of Physical Medicine and Precision Rehabilitation of Chongqing Municipal Health Commission, The…. Hauptthemen laut MEDLINE: Extracellular Vesicles, Mesenchymal Stem Cells, Atherosclerosis, Epithelial-Mesenchymal Transition. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The National Natural Science Foundation of China, Chongqing Natural Science Foundation, Chongqing Medical Scientific Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endothelial–mesenchymal transition (EndMT) of vascular endothelial cells (VECs) plays a pivotal role in the progression of atherosclerosis (AS). The therapeutic potential of reversing EndMT holds promise for AS treatment. In this study, bone marrow mesenchymal stem cells (BMSCs)–derived extracellular vesicles (EVs) are engineered as nanostructured drug carriers with two functional modules, targeting module and functional protein module. In targeting module, to specifically target VECs, the cholesterol‐modified aptamers of VECs‐specific protein vascular endothelial growth factor (VEGF) are assembled to the engineered EVs. In functional protein module, engineered EVs are infected with recombinant silent information regulator 2–related enzyme 1 (SIRT1) adenoviruses, with the achievement of SIRT1 protein overexpression on the surface. Upon targeted aggregation around the mesenchymalized VECs, the engineered EVs are taken up by VECs and the loaded SIRT1 is released into VECs. Then, SIRT1 can effectively reverse VECs‐EndMT by activating nuclear factor‐erythroid 2–related factor 2 (Nrf2) and regulating oxidative stress response. The targeted efficacy for precision therapy in AS has been successfully demonstrated both in vitro and in vivo, by reversing EndMT and reducing inflammation in atherosclerotic plaques. This study provides a novel strategy for AS treatment and offers insights into the next generation of regenerative medicine technologies based on engineered EVs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesMesenchymal Stem CellsAtherosclerosisEpithelial-Mesenchymal TransitionHumansAnimalsSirtuin 1Endothelial CellsNF-E2-Related Factor 2Vascular Endothelial Growth Factor AMaleMiceEndothelial-Mesenchymal Transition

Stichwörter der Autor:innen

atherosclerosisbone marrow mesenchymal stem cellsextracellular vesiclessilent information regulator 2–related enzyme 1vascular endothelial cells

Substanzen

Sirtuin 1NF-E2-Related Factor 2Vascular Endothelial Growth Factor ASIRT1 protein, human

Autor:innen und Institutionen

  • Department of Rehabilitation Medicine, Key Laboratory of Physical Medicine and Precision Rehabilitation of Chongqing Municipal Health Commission, The First Affiliated Hospital of Chongqing Medical University, Chongqing,…
  • Department of Clinical Laboratory Medicine, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
  • Army 953th Hospital (Shigatse Branch, Xinqiao Hospital), Third Military Medical University, Shigatse, China.

ORCID-Profile: Ming Chen, Yan Pi

Förderung

  • The National Natural Science Foundation of China
  • Chongqing Natural Science Foundation
  • Chongqing Medical Scientific Research Project

Zitieren

APA

Chen, Z., Chang, K., Yang, S., Deng, R., He, Y., Zhang, L., Chen, M., Bai, D., & Pi, Y. (2025). Engineered Mesenchymal Stem Cell–Derived Extracellular Vesicles Reverse Endothelial–Mesenchymal Transition in Atherosclerosis. Journal of Extracellular Vesicles, 14(6). https://doi.org/10.1002/jev2.70099

Vancouver

Chen Z, Chang K, Yang S, Deng R, He Y, Zhang L, et al. Engineered Mesenchymal Stem Cell–Derived Extracellular Vesicles Reverse Endothelial–Mesenchymal Transition in Atherosclerosis. Journal of Extracellular Vesicles. 2025;14(6). doi:10.1002/jev2.70099

BibTeX
@article{Chen2025,
  author = {Chen, Zhuo and Chang, Kai and Yang, Sha and Deng, Ruijia and He, Yuan and Zhang, Ligai and Chen, Ming and Bai, Dingqun and Pi, Yan},
  title = {Engineered Mesenchymal Stem Cell–Derived Extracellular Vesicles Reverse Endothelial–Mesenchymal Transition in Atherosclerosis},
  journal = {Journal of Extracellular Vesicles},
  year = {2025},
  volume = {14},
  number = {6},
  doi = {10.1002/jev2.70099}
}
Kostenlos starten →